Preview Mode Links will not work in preview mode

Apr 11, 2019

Last time I looked this up online, there were more than 5000 companies offering digital medicine tools. Which ones worked? Which ones are less good than others? Which ones have not been tested? How were they tested: apples to apples or a whole fruit basket of standards? If you’re a clinician or the head of population health or an insurance carrier and you’re trying to figure out whether a digital tool could help solve a problem your patients are having … at this juncture, may the force be with you and I hope you know how to use Excel.

The Digital Therapeutics Alliance (DTA) aims to put definitions and standards around what can be legitimately called a digital therapeutic and how these tools are best deployed so that patients are best equipped to get the best possible outcomes. Today I speak with Megan Coder, executive director of the Digital Therapeutics Alliance.

You can learn more at

Megan Coder, PharmD, MBA, is executive director of the Digital Therapeutics Alliance (DTA), whose mission is to broaden the understanding, adoption, and integration of clinically validated digital therapeutic solutions into mainstream health care through education, advocacy, and research. With more than a decade of experience in the health care industry, Megan’s expertise extends from strategic growth and partnership development within the digital health sector to the direct delivery of patient care.

01:50 What the Digital Therapeutics Alliance is.
02:59 Defining a digital therapeutic.
03:50 What is vs what isn’t a digital therapeutic.
05:08 What it means to be a digital therapeutic.
06:19 Extending clinical care to a patient outside of the clinical care environment.
07:54 Digital therapeutics Megan is currently excited about.
10:48 Learn more about WellDoc with Anand Iyer in EP102.
11:02 Learn more about Propeller Health in EP32 with Kevin Houlihan.
12:05 Digital therapeutics and digital formularies.
13:09 Managing and prescribing digital therapeutics on an individual patient level.
15:22 Why the DTA exists and the questions it’s answering.
18:09 Legitimate claims vs really good marketing.
20:34 “How do we start to clarify that process and bring a little … more continuity and consistency into this world?”
22:57 Disrupting without interrupting.
25:24 Megan’s advice to providers: knowing clinical needs and gaps.
27:31 Megan’s advice for insurance carriers.
28:32 Love the problem, not the solution.

You can learn more at